跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
張 又升
副教授
,
過敏免疫風濕科
主治醫師
,
衛生福利部雙和醫院
https://orcid.org/0000-0002-2622-7524
電子郵件
yschang
tmu.edu
tw
h-index
1106
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2011
2024
每年研究成果
概覽
指紋
網路
專案
(4)
研究成果
(80)
資料集
(9)
類似的個人檔案
(10)
指紋
查看啟用 Yu-Sheng Chang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Systemic Lupus Erythematosus
100%
Cohort Analysis
74%
Hazard Ratio
48%
Rheumatoid Arthritis
34%
Autoimmune Disease
22%
Proportional Hazards Model
18%
Cohort Effect
18%
Sjoegren Syndrome
15%
Rheumatology
13%
Myasthenia gravis
12%
Autoimmune Rheumatic Disease
12%
Internal Medicine
12%
Tuberculosis
12%
Pneumocystis Jirovecii
12%
Kidney Transplantation
12%
Acute Pancreatitis
12%
Proteomics
12%
Parkinson's Disease
12%
Autoantibodies
12%
Medicine
10%
Malignant Neoplasm
9%
Kidney Graft
9%
Division
9%
Immunology
9%
Popliteal Cyst
9%
Lung Tuberculosis
8%
Infection
8%
Prevalence
8%
Disease
8%
Systemic Scleroderma
8%
Treatment Response
8%
Osteoarthritis
8%
Hip Fracture
7%
Biological Product
7%
End Stage Renal Disease
7%
Survival Analysis
7%
Health Care Cost
6%
Knee Osteoarthritis
6%
Idiopathic Thrombocytopenic Purpura
6%
Lupus Erythematosus
6%
Systemic Mycosis
6%
Rituximab
6%
Primary Ovarian Insufficiency
6%
Protein Losing Enteropathy
6%
Restylane
6%
Obstructive Sleep Apnea
6%
Aortic Aneurysm
6%
Aortic Dissection
6%
Virus Infection
6%
Pediatrics
6%
Immunology and Microbiology
Systemic Lupus Erythematosus
56%
Inflammatory Arthritis
54%
Autoantibodies
35%
Comorbidity
30%
Autoimmune Disease
26%
Sjögren's Syndrome
24%
Myasthenia gravis
21%
Isotype
18%
Prevalence
15%
Systemic Scleroderma
15%
Immunoglobulin A
14%
Immunoglobulin M
14%
Autoimmune Rheumatic Disease
12%
Osteoarthritis
10%
Nephritis
10%
Lupus Erythematosus
10%
Ankylosing Spondylitis
9%
Population
9%
Systemic Autoimmune Disease
8%
Heavy Chain
8%
Prednisolone
7%
Inter-Alpha-Trypsin Inhibitor
7%
Thyroiditis
7%
Idiopathic Thrombocytopenic Purpura
7%
Oxidative Stress
6%
Viral Disease
6%
Coronary Artery
6%
Decision Trees
6%
Herpes Simplex Virus
6%
Interferon Type I
6%
Pneumocystis Jiroveci
6%
Interleukin 17
6%
C1-Inhibitor
6%
Interleukin 23
6%
Rituximab
6%
Cell Membrane
6%
Wellbeing
6%
Blood Brain Barrier
6%
Mitochondrion
6%
Oxidation Reduction Potential
6%
Decision Making
6%
Allergic Rhinitis
6%
Acute Pancreatitis
6%
Mycobacterium Tuberculosis
6%
Hepatitis C
6%
Gout
6%
Periodontal Ligament
6%
Organoid
6%
COVID-19
6%
Synovitis
6%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Lupus Erythematosus
54%
Rheumatoid Arthritis
35%
Cohort Study
34%
Autoantibodies
32%
Autoimmune Disease
26%
Syndrome
22%
Sjoegren Syndrome
19%
4 Hydroxynonenal
16%
Malonaldehyde
15%
Systemic Sclerosis
14%
Comorbidity
13%
Immunoglobulin M
12%
Sleep Disordered Breathing
12%
Rheumatic Disease
12%
Clinical Feature
12%
Hepatitis C
10%
Tuberculosis
9%
Ankylosing Spondylitis
8%
Myasthenia gravis
8%
Immunoglobulin A
8%
Disease
8%
Disease Activity
8%
Hepatitis B Virus
7%
Hip Fracture
7%
Thyroiditis
6%
Complement Component C1s Inhibitor
6%
Hyaluronic Acid
6%
Proton Pump Inhibitor
6%
Jaw Osteonecrosis
6%
Chronic Hepatitis C
6%
Lesinurad
6%
Trypsin Inhibitor
6%
Virus Hepatitis
6%
Bisoprolol
6%
Pneumocystis Jiroveci
6%
Coronary Artery Disease
6%
Histamine H1 Receptor Antagonist
6%
Liver Cell Carcinoma
6%
Knee Osteoarthritis
6%
Hepatitis C Virus
6%
Carvedilol
6%
Chronic Obstructive Lung Disease
6%
Metoprolol
6%
Randomized Controlled Trial
6%
Subarachnoid Hemorrhage
6%
Interferon
6%
Immunoglobulin G
6%
Hyperuricemia
6%
Posterior Reversible Encephalopathy Syndrome
6%
Parkinson's Disease
6%
